Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pCI-neo-C1QBP is a recombinant DNA expression plasmid used in molecular biology research to induce the overexpression of the Complement component 1, q subcomponent binding protein (C1QBP) in mammalian cells. The construct utilizes the pCI-neo mammalian expression vector, which features the human cytomegalovirus (CMV) immediate-early enhancer/promoter for high-level constitutive expression and a neomycin resistance gene for selection in mammalian cells. In the context of oncology research, specifically triple-negative breast cancer (TNBC), pCI-neo-C1QBP is employed to study the oncogenic role of C1QBP, a protein localized primarily in the mitochondria that regulates cell proliferation, apoptosis, and metabolic signaling. Studies using this plasmid have demonstrated that C1QBP overexpression promotes the growth and survival of MDA-MB-231 breast cancer cells, identifying C1QBP as a potential therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pCI-neo-C1QBP.